Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17465256 | 0.91 | HRH3 (0.56) | HRH3HRH4PDE2ABCHEMAOB | |
| SCHEMBL16254956 | 0.86 | GAA (0.58) | HRH3HRH4ALDH1A1GAA | |
| SCHEMBL13727922 | 0.86 | GAA (0.58) | HRH3HRH4ALDH1A1GAA | |
| SCHEMBL6189062 | 0.84 | ALDH1A1 (0.59) | HRH3HRH4ALDH1A1GAA | |
| SCHEMBL20803941 | 0.84 | BCHE (0.51) | HRH3PDE2ABCHEMAOBROCK2 | |
| SCHEMBL13726832 | 0.83 | HPGD (0.60) | HRH3HRH4BCHEACHEALDH1A1 | |
| SCHEMBL8244556 | 0.83 | HRH3 (0.54) | HRH3HRH4ROCK2ALDH1A1 | |
| SCHEMBL82814 | 0.83 | HPGD (0.60) | HRH3HRH4BCHEACHEALDH1A1 | |
| SCHEMBL19851034 | 0.81 | ALDH1A1 (0.56) | HRH3HRH4PDE2ABCHEACHE | |
| SCHEMBL24451870 | 0.81 | PDE2A (0.47) | HRH3PDE2ABCHEMAOBROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | CHKA, CHKB, CEPT1 | HRH3 757/4885HRH4 1302/4885PDE2A 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.